CN118355033A - 包含抗NRP2a抗体的组合物和方法 - Google Patents
包含抗NRP2a抗体的组合物和方法 Download PDFInfo
- Publication number
- CN118355033A CN118355033A CN202280080506.0A CN202280080506A CN118355033A CN 118355033 A CN118355033 A CN 118355033A CN 202280080506 A CN202280080506 A CN 202280080506A CN 118355033 A CN118355033 A CN 118355033A
- Authority
- CN
- China
- Prior art keywords
- cancer
- antigen
- antibody
- optionally
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272374P | 2021-10-27 | 2021-10-27 | |
| US63/272,374 | 2021-10-27 | ||
| PCT/US2022/078780 WO2023076998A1 (en) | 2021-10-27 | 2022-10-27 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118355033A true CN118355033A (zh) | 2024-07-16 |
Family
ID=86158721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280080506.0A Pending CN118355033A (zh) | 2021-10-27 | 2022-10-27 | 包含抗NRP2a抗体的组合物和方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240417476A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4423142A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540083A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118355033A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022375785A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234409A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023076998A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| AU2020358854B2 (en) | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| NZ594514A (en) * | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| JP5812418B2 (ja) * | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| EP2700652B1 (en) * | 2011-04-18 | 2018-12-19 | The University of Tokyo | Diagnosis and treatment of cancer using anti-itm2a antibody |
| DK2935331T3 (en) * | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| EP3116906A1 (en) * | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
| US11104724B2 (en) * | 2016-05-23 | 2021-08-31 | New York University | Compositions and methods for antibodies targeting staphylococcal leukotoxins |
| US12365916B2 (en) * | 2017-10-30 | 2025-07-22 | Miltenyi Biotec B.V. & Co. KG | Adapter-based retroviral vector system for the selective transduction of target cells |
| WO2019195770A1 (en) * | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| MX2021011489A (es) * | 2019-04-01 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. |
| ES3049416T3 (en) * | 2019-09-23 | 2025-12-16 | Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P | Antibodies for the diagnosis and/or treatment of atherosclerosis |
| AU2020358854B2 (en) * | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| WO2021202590A1 (en) * | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
-
2022
- 2022-10-27 AU AU2022375785A patent/AU2022375785A1/en active Pending
- 2022-10-27 CN CN202280080506.0A patent/CN118355033A/zh active Pending
- 2022-10-27 CA CA3234409A patent/CA3234409A1/en active Pending
- 2022-10-27 WO PCT/US2022/078780 patent/WO2023076998A1/en not_active Ceased
- 2022-10-27 US US18/703,912 patent/US20240417476A1/en active Pending
- 2022-10-27 EP EP22888492.0A patent/EP4423142A4/en active Pending
- 2022-10-27 JP JP2024525338A patent/JP2024540083A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022375785A1 (en) | 2024-04-11 |
| WO2023076998A1 (en) | 2023-05-04 |
| EP4423142A1 (en) | 2024-09-04 |
| JP2024540083A (ja) | 2024-10-31 |
| CA3234409A1 (en) | 2023-05-04 |
| EP4423142A4 (en) | 2025-10-22 |
| US20240417476A1 (en) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12065495B2 (en) | Compositions and methods comprising anti-NRP2 antibodies | |
| CN114746120B (zh) | 包含抗nrp2抗体的组合物和方法 | |
| US20180282402A1 (en) | Anti-hrs antibodies and combinaton therapies for treating cancers | |
| JP2024075762A (ja) | Nrp2関連疾患を治療するための組成物および方法 | |
| US20240417476A1 (en) | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES | |
| WO2021257808A2 (en) | Antibodies to fibroblast activation protein and b7h3 | |
| US20250188170A1 (en) | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES | |
| HK40008971B (en) | Monovalent asymmetric tandem fab bispecific antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Luke G. Borman Inventor after: Zhang Yuting Inventor after: Caitlin lauch Inventor after: Leslie Ann Green Inventor before: Luke G. Borman Inventor before: Zhang Yuting Inventor before: Caitlin lauch Inventor before: Leslie A. Nagel |